Great discount for report package
STUTTGART, Germany I May 30, 2018 I La Merie Publishing announces the release of a report bundle about TCR-based immunotherapeutics at a 33% discount on the list prices:
Report Package: TCR-Based Antibody and T-Cell Immunotherapy
T-Cell Receptor (TCR)-based therapeutic cells and recombinant antibodies or antibody fusion proteins have emerged as a new class of effective cancer therapeutics. Both treatment modalities have in common that they are directed to intracellular targets wich are estimated to be 3-4 times more frequent than surface protein targets. However, these intracellular cancer targets are not accessible to traditional monoclonal antibody or chimeric antigen receptor (CAR) T-cell therapy. While TCR engineered T-cells exert their effector function via the cytotoxicity of T-cells, antibodies can act via their intrinsic effects (ADCC, CDC) or by enhancing them as antibody-drug conjugates or T-cell redirecting bispecific antibodies. TCR-based treatments are especially promising for the treatment of solid tumors
This report package includes two full reports covering TCR-based T-cell and recombinant antibody (fusion protein) immunotherapy of cancer.
The original reports were published in January and May 2018, respectively:
and
Detailed report descriptions, tables of contents and samples from the reports can be found on the respective product page. The reports can be acquired at
The report package can be acquired at La Merie Publishing‘ online store https://www.pipelinereview.com/index.php/store-online/report-package-tcr-based-antibody-and-t-cell-immunotherapy-detail . There you will find samples pages, a detailed Tables of Contents, lists of Tables and of companies discussed in the reports.
About La Merie Publishing
La Merie Publishing prepares brief and full reports as well as competitor analysis reports, the latter in a tabulated format with structured listings of industry-relevant data. One of our top-selling listings are the annual editions of „Blockbuster Biologics – Sales of Recombinant Therapeutic Antibodies & Proteins“. La Merie Publishing products can be purchased in our online store at www.pipelinereview.com or at selected Resellers.
The focus of our products is directed towards therapeutic biologics, such as antibodies, proteins, peptides, vaccines and gene & cell therapy. We pay special attention to biosimilar antibodies and proteins, antibody drug conjugates, bispecific antibodies, TCR & CAR engineered antibodies, mRNA vaccines & therapeutics, oncolytic viruses and immuno-oncology in general.
To leverage our expertise and knowledge accumulated in our in-house database, we offer consultancy services for corporate customers, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest for our clients.
SOURCE: La Merie Publishing
Post Views: 191
Great discount for report package
STUTTGART, Germany I May 30, 2018 I La Merie Publishing announces the release of a report bundle about TCR-based immunotherapeutics at a 33% discount on the list prices:
Report Package: TCR-Based Antibody and T-Cell Immunotherapy
T-Cell Receptor (TCR)-based therapeutic cells and recombinant antibodies or antibody fusion proteins have emerged as a new class of effective cancer therapeutics. Both treatment modalities have in common that they are directed to intracellular targets wich are estimated to be 3-4 times more frequent than surface protein targets. However, these intracellular cancer targets are not accessible to traditional monoclonal antibody or chimeric antigen receptor (CAR) T-cell therapy. While TCR engineered T-cells exert their effector function via the cytotoxicity of T-cells, antibodies can act via their intrinsic effects (ADCC, CDC) or by enhancing them as antibody-drug conjugates or T-cell redirecting bispecific antibodies. TCR-based treatments are especially promising for the treatment of solid tumors
This report package includes two full reports covering TCR-based T-cell and recombinant antibody (fusion protein) immunotherapy of cancer.
The original reports were published in January and May 2018, respectively:
and
Detailed report descriptions, tables of contents and samples from the reports can be found on the respective product page. The reports can be acquired at
The report package can be acquired at La Merie Publishing‘ online store https://www.pipelinereview.com/index.php/store-online/report-package-tcr-based-antibody-and-t-cell-immunotherapy-detail . There you will find samples pages, a detailed Tables of Contents, lists of Tables and of companies discussed in the reports.
About La Merie Publishing
La Merie Publishing prepares brief and full reports as well as competitor analysis reports, the latter in a tabulated format with structured listings of industry-relevant data. One of our top-selling listings are the annual editions of „Blockbuster Biologics – Sales of Recombinant Therapeutic Antibodies & Proteins“. La Merie Publishing products can be purchased in our online store at www.pipelinereview.com or at selected Resellers.
The focus of our products is directed towards therapeutic biologics, such as antibodies, proteins, peptides, vaccines and gene & cell therapy. We pay special attention to biosimilar antibodies and proteins, antibody drug conjugates, bispecific antibodies, TCR & CAR engineered antibodies, mRNA vaccines & therapeutics, oncolytic viruses and immuno-oncology in general.
To leverage our expertise and knowledge accumulated in our in-house database, we offer consultancy services for corporate customers, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest for our clients.
SOURCE: La Merie Publishing
Post Views: 191
